Concord Medical Announces Obtaining Large Medical Equipment Procurement License For Its Proton Therapy Equipment
Concord Medical Announces Obtaining Large Medical Equipment Procurement License For Its Proton Therapy Equipment
Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE:CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that Guangzhou Concord Cancer Center ("Guangzhou Hospital"), a PRC subsidiary of the Company offering comprehensive cancer care services, has obtained the large medical equipment procurement license (the "License") for its proton equipment.
中国专门从事癌症治疗、研究、教育和预防的医疗保健提供商协和医疗服务控股有限公司（“协和医疗” 或 “公司”）（纽约证券交易所代码：CCM）今天宣布，该公司提供综合癌症护理服务的中国子公司广州协和癌症中心（“广州医院”）已获得质子设备的大型医疗设备采购许可证（“许可证”）。
As previously disclosed in the Company's annual report for the fiscal year ended December 31, 2023, Guangzhou Hospital has completed the installment of the proton equipment in September 2020 and commenced its clinical trial in November 2022. Guangzhou Hospital has also subsequently submitted the application for the License for such proton equipment, planning to offer proton therapy treatment services at its proton center. On September 14, 2024, the National Health Commission of the PRC announced to grant approval to Guangzhou Hospital's application for the License. Guangzhou Hospital plans to start its proton therapy treatment services at its earliest convenience after necessary preparations.
正如公司此前在截至2023年12月31日的财政年度的年度报告中披露的那样，广州医院已于2020年9月完成质子设备的分期付款，并于2022年11月开始临床试验。随后，广州医院也提交了此类质子设备的许可证申请，计划在其质子中心提供质子治疗服务。2024年9月14日，中华人民共和国国家卫生委员会宣布批准广州医院的许可证申请。广州医院计划在必要准备后尽早启动质子治疗服务。
